Terkini

Gerak Cepat, TIM ATP Community Door To Door Kampanye Dan Sebar Baliho

POLITIK

Direktur Kampanye Prabowo Presiden 2024 Wilayah Sulsel H. A. Anhar Rahman S.Sos, Resmikan Rumah Pemenangan Gerindra Di Bantaeng

Politics

Innalillahi, Adik Kandung Pemred Beritasulsel.com Meninggal Dunia

News

Laga Silaturrahim Tour dE Jogja, Ikatek FC Akui Kolektifitas Kagama FC

World

Diduga Ada Tindak Pidana Korupsi Dan Penipuan Terkait Bantuan Ternak Sapi Dari BPBD Jeneponto Untuk KPM

HUKUM

Silaturahim, Sejumlah OPD Pemerintah Provinsi Sulsel Berkunjung ke Huadi Bantaeng

Bantaeng

Penculikan Anak Itu Hoaks, Bupati Bantaeng Minta Proses Pembelajaran Berjalan Normal

Pemkab Bantaeng

Tarif Penerbitan SIM Naik, PMII Nilai Sat Lantas Polres Bulukumba Tidak Transfaran

Bulukumba

Raih Peringkat Pertama UPP Saber Pungli Se Sulsel, Kapolres ANDI KUMARA: Ini Semua Berkat Kerja Personil Secara Profesional

POLISI HUMANIS

Bank Sulselbar Bulukumba Lounching “SimPel”, Rio Subagyo : Ajak Siswa Menabung Sejak Dini

EKONOMI

Rencana Kenaikan Harga BBM, Pemkab Bantaeng: Kami Ikut Keputusan Pemerintah Pusat

News
Persatuan Wartawan Indonesia Larang 20.000 Anggotanya Ikut UKW Lembaga Abal-abal dan Tak Patuhi UU Pers

Persatuan Wartawan Indonesia Larang 20.000 Anggotanya Ikut UKW Lembaga Abal-abal dan Tak Patuhi UU Pers

News
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis LONDON, UK - EQS Newswire - 10 June 2022 - Financial information from over 100 multinational drug companies, involving over 70,000 data points, have been accumulated over the past 35 years to create a pharmaceutical database. All our data (sales, COGS, SG&A, R&D and other income) have been derived from annual reports, regulatory filings and company presentations, and then analysed, wherever possible, in a like-for-like manner, irrespective of how each company presents the data. This is a key differentiator to competitive products and is important because all company management teams report "adjusted", "core", or "non-GAAP" earnings to show themselves in the best possible light. However, different inclusion/exclusion criteria in the generation of these adjustments lead to distortions and variability. Although some of the companies are multi-divisional, another key differentiator is the extraction and analysis of data for the pharmaceutical segment only. This product is unique because it analyses the individual cost components of each company over time and generates pharma industry weighted averages, allowing peer and industry comparisons to be made. It also generates individual company and industry-wide underlying operating profit (EBIT), both pre-R&D and post R&D. Historically, data from over 100 companies has been accumulated, but industry consolidation means that just 40 are included currently, which command an estimated 76% of the global drug industry. The main exceptions are the Chinese companies where insufficient data are available on a consistent basis. Current companies included in dataset: Click here to find out more: https://hardmanandco.com/2021-pharma-statistics-long-term-cost-underlying-ebit-analysis/ Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis

World

Eratkan Silaturahmi, Kapolda Metro Jaya Bersama Pimpinan Serikat Pekerja dan Wartawan Gelar Olahraga Bersama

News

Dua Perusahaan yang Memprodusen Minyak Goreng Ditinjau Kapolres Jaktim

News
Sudah ditampilkan semua
Tutup